AMPX has now dropped to $14.12 — comfortably below every price at which insiders were selling just weeks ago, leaving the stock in an uncomfortable no-man's land with shorts still firmly in position.
The short interest story has evolved since last week's note. The 19.4% of free float currently borrowed and sold represents a modest week-on-week increase of about 2%, continuing the grinding build that began in early June. Short interest is now roughly 11% higher than a month ago — the accumulation has been deliberate rather than explosive. Crucially, the borrow market offers shorts little friction. Cost to borrow has fallen sharply, down nearly 20% on the week to just 0.34% — a negligible carry cost that removes any economic pressure on existing short positions. Availability is wide open at 365%, meaning roughly three-and-a-half shares remain available for every one already borrowed. That is not a setup primed for a squeeze; it is a setup where shorts face minimal headwinds.
Options positioning adds a layer of nuance. The put/call ratio of 0.67 is essentially in line with its 20-day average — the z-score of 0.35 is unremarkable — which suggests options traders are neither rushing to hedge nor loading up on upside calls. The PCR has drifted down from near its 52-week high of 0.72 in late May, a quiet de-escalation of the hedging pressure that built ahead of the May earnings print. The combination of stable options positioning and expanding short interest implies the bears are expressing their view directly through the short book rather than through puts.
The Street remains uniformly bullish on paper, but the gap between targets and price has grown stark. Clear Street initiated coverage with a Buy and a $33 target on June 3 — the most recent action — while earlier targets from Needham, B. Riley, and Craig-Hallum cluster in the $20–$22 range. Against a stock now at $14.12, even the most conservative of those targets implies roughly 40% upside. Bulls point to the customer expansion story — 93 clients, 43 of them new — and long-term margin projections of 25–27% by 2028. Bears see a company still burning cash, with deeply negative ROA and a price-to-book near 18x that prices in a commercialisation trajectory that has yet to materialise. The ORTEX short score of 59 and an EPS momentum rank in the 1st percentile over the last 30 days reflect that tension, as near-term fundamental momentum has turned sharply negative even as growth scores remain elevated.
The institutional picture offers some ballast. BlackRock added roughly 400,000 shares in the most recent reporting period, and Driehaus and Two Sigma each built meaningful new positions in Q1. Jane Street added over 2.8 million shares. That institutional accumulation provides a degree of structural support, but it also means the stock has sophisticated holders who can exit efficiently if the narrative deteriorates further — and the insider selling pattern reinforces the concern. Chairman Dixon sold 85,000 shares on June 15 at $17.17, then 40,000 on June 9 at $19.13. The stock closed Tuesday at $14.12. Those who sold alongside him have done better than those who bought the dip.
Peer context is consistent with sector weakness rather than AMPX-specific distress. Close peer ENVX fell more than 10% on both the day and the week — a worse performance than AMPX — while STEM dropped just under 2% on the week. NRGV bucked the trend with a 3.4% weekly gain. The sector-wide pressure makes it harder to isolate a catalyst specific to AMPX, but it also means the stock is being weighed by a macro headwind that all battery-technology names are navigating simultaneously. The next scheduled earnings event is August 6 — the period between now and that date, with shorts holding a near-20% position, borrow essentially free, and insiders having stepped back from buying, is the interval worth watching most closely.
See the live data behind this article on ORTEX.
Open AMPX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
